Chip stocks fall with Nvidia after data center rev disappointment
GAITHERSBURG, Md. - Emergent BioSolutions Inc. (NYSE:EBS), a $373 million market cap biotech company with nearly $1 billion in annual revenue, has secured a contract modification to deliver additional doses of CNJ-016® (VIGIV) to the Administration for Strategic Preparedness and Response (ASPR), the company announced Tuesday.
The modification comes under an existing 10-year contract with the U.S. Department of Health and Human Services for smallpox preparedness. VIGIV is a treatment for complications due to smallpox vaccination, including eczema vaccinatum and progressive vaccinia. According to InvestingPro analysis, the company maintains strong liquidity with a current ratio of 6.32, suggesting robust operational capability to fulfill government contracts.
"Securing this contract modification for VIGIV treatment underscores Emergent’s ongoing partnership with the U.S. government to support its overall smallpox preparedness strategy," said Paul Williams, senior vice president at Emergent.
This award follows the company’s recently announced contract amendment for BAT® [Botulism Antitoxin Heptavalent] with ASPR.
VIGIV is an Immune Globulin indicated for treating complications from vaccinia vaccination, though it is not indicated for postvaccinial encephalitis or isolated vaccinia keratitis. The medication carries warnings about potential interactions with glucose monitoring systems, as maltose in the product may give falsely high blood glucose readings with certain testing methods.
Common adverse reactions to VIGIV reported in clinical trials include headache, nausea, rigors, and dizziness.
Emergent BioSolutions has been developing protective solutions for public health threats including smallpox, mpox, botulism, and anthrax for over 25 years, according to the press release statement. While the company faces near-term revenue challenges, InvestingPro analysts project a return to profitability this year, with the stock currently trading below its Fair Value. Get access to 8 more exclusive InvestingPro Tips and comprehensive analysis through the Pro Research Report.
In other recent news, Emergent BioSolutions reported a remarkable 656% increase in net income for Q1 2025, reaching $68 million, despite a decline in total revenues to $222 million. The company continues to hold a leadership position in the naloxone market, with NARCAN nasal spray being a significant contributor. Emergent also secured a $62.4 million contract modification for its botulism antitoxin with the U.S. Department of Health and Human Services, reinforcing its role in medical countermeasures. Additionally, the company announced its inclusion in the Russell 3000 Index, effective after market close on June 27, 2025. Emergent has expanded its NARCANDirect platform to include KLOXXADO Nasal Spray 8 mg, enhancing access to opioid overdose treatments. The company introduced Convenience Kits for overdose response, adding to its product offerings. Analysts from firms like H.C. Wainwright have noted these developments, which align with Emergent’s strategic initiatives for growth and profitability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.